Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against ChemoCentryx, Inc.

NEW YORK, May 6, 2021 / PRNewswire / – Bernstein Liebhard, a nationally recognized investor rights law firm, announces that a class action lawsuit has been filed on behalf of investors who have bought or acquired the securities of ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”). ) (NASDAQ: CCXI) by November 26, 2019 by May 3, 2021 (the “Class Period”). The lawsuit has been filed The United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

If you have purchased ChemoCentryx securities and / or would like to discuss your statutory rights and options, please visit or contact the class action lawsuit against ChemoCentryx shareholders Joseph R. Seidman, Jr. toll free at (877) 779-1414 or [email protected]

The complaint alleges that during the classroom, the defendants made false and / or misleading statements and / or failed to disclose that: (1) the study design of the Phase III ADVOCATE study had problems with the interpretability of the experimental data used to define a raises clinically meaningful benefits of avacopan and its role in the treatment of ANCA-associated vasculitis (2) The data from the Phase III ADVOCATE study raise serious safety concerns for avacopan. (3) These issues raised serious concerns about the viability of the ChemoCentryx NDA for Avacopan for the treatment of ANCA-associated vasculitis. and (4) as a result of the foregoing, Defendants’ public statements at all relevant times have been materially false and misleading.

On May 4, 2021The US Food and Drug Administration (“FDA”) released a briefing document regarding the NDA of ChemoCentryx for Avacopan. In the document, the FDA wrote that “[a]Although the primary efficacy comparisons were statistically significant, the review team identified several problem areas that raise uncertainties about the interpretability of these data and the clinical power of these results[.]”In the briefing document, the FDA also raised serious safety concerns about avacopan in the treatment of ANCA-associated vasculitis.

In the news, ChemoCentryx common stock fell over 45% in one day May 3, 2021 Closing price from $ 48.82 to a May 4, 2021 near $ 26.63 per share with unusually high trading volume.

If you want to appear as the lead plaintiff, you must move the court at the latest July 6, 2021. A lead plaintiff is a representative party who acts on behalf of other class members in directing the dispute. Your ability to partake in a recovery does not require you to be the lead plaintiff. If you don’t take action, you may remain an absent class member.

If you have purchased ChemoCentryx securities and / or would like to discuss your legal rights and options, please visit https://www.bernlieb.com/cases/chemocentryxinc-ccxi-shareholder-class-action-lawsuit-fraud-stock-396 / apply / or contact Joseph R. Seidman, Jr. toll free at (877) 779-1414 or [email protected]

Bernstein Liebhard LLP has been recovering since 1993 $ 3.5 billion for its customers. In addition to representing individual investors, the firm has been hired by some of the country’s largest public and private pension funds to oversee their assets and litigate on their behalf. Because of its litigation success with hundreds of lawsuits and class actions, the firm has been featured on the National Law Journal’s Hot List thirteen times and on The Legal 500 for ten consecutive years.

LAWYER. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779- 1414. The lawyer responsible for this complaint in the State of Connecticut is Michael S. Bigin. Past results do not guarantee or forecast a similar result with respect to future matters.

Contact information
Joseph R. Seidman, Jr.
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]

SOURCE Bernstein Liebhard LLP

similar links

http://www.bernlieb.com

Comments are closed.